Preclinical MR-PET
Stephen Sawiak1

1Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom

Synopsis

MR-PET offers new horizons for quantitative, specific assessment in animal models. Here the basic principles are described along with advantages and pitfalls.

Target audience

Basic scientists in biomedicine, physics or clinicians who wish to learn about positron-emission tomography (PET) for molecular imaging in combination with MRI.

Outcome and objectives

Attendees will learn

1. Basic principles of PET imaging
(positron emission, detection, attenuation correction, reconstruction)

2. Common tracers used in preclinical research, their use, advantages and limitations

3. How to extract useful information from PET images

4. Pitfalls and problems in MR-PET

Purpose

PET offers highly sensitive molecular imaging following tracers involved in biological processes. Most tracers are specific and can be quantified: both weak areas for MRI. Unfortunately, spatial and temporal resolution can be poor. Together, MRI and PET are complementary: the shortcomings of MRI for addressing specific molecular or quantitative questions can be addressed using a tracer. The shortcomings of PET – low spatial and temporal resolution – are addressed by MRI. This purpose of this talk is to introduce the concepts of PET to an audience familiar with MRI and explain how both modalities can be combined to obtain information hard to obtain from either method independently.

Methods

Historically, the largest obstacle to combining MR with PET has been the interference of the magnetic fields with the photomultiplier tubes used to the detect gamma photons emitted in the PET experiment. The advent of avalanche photodiodes and later silicon photomultiplier tubes has allowed detectors to be incorporated within or adjacent to MR magnets so that a range of combined machines are available: either adjoining or self-contained for simultaneous MR-PET acquisitions.

Although sequential systems do not require much compromise in the design of either machine, the real promise of MR-PET is the benefit gained by having truly coregistered data at the time of acquisition. For example, rapidly acquired MRI can be used for motion correction in the PET data. Cross-validation of techniques can be performed (e.g. ASL perfusion vs. PET perfusion in the brain; or late-gadolinium enhancement vs. FDG infarct in cardiac applications).

PET can be highly quantitative when proper corrections are made to the data. One of these corrections (important with larger animals) concerns signal attenuation which differs depending on the tissue type. It can be addressed by irradiating the subject with a known source that revolves around, thus giving a direct measure of the attenuation at each point. MR images acquired simultaneously can be used to model tissue attenuation based on MR contrast. The approach must be used carefully as some substances (in particular bone and air) have very different attenuating effects but similar MR contrast in most sequences.

MRI data can be used to reconstruct MR-PET data taking information into account that is not available during the PET scan. For example, co-injecting a gadolinium contrast agent with the PET tracer to obtain arterial input functions.

Modelling of the data seen to obtain information about biological processes can be complicated. A full model requires the solution of differential equations which can explain the biological interactions of the radiotracer injected with different tissues: either through receptor binding (e.g. in dopamine tracers) or via cell metabolism (FDG). Full kinetic analysis is time consuming and requires invasive blood sampling which may not be possible in small animals. Simple models are widely encouraged as an alternative, using standardised uptake values, perhaps with a reference tissue. The should be validated against a full model, however, to ensure they offer useful measures of the biological processes of interest.

Conclusion

MR-PET offers quantitative imaging that can be specific: both usually problematic in MR experiments alone. MRI offers high spatial resolution. The potential impact of the combined modality has still not been fully explored but it offers exciting opportunities to biomedical researchers to extend what can be obtained from preclinical models beyond MRI. This talk will discuss how the combination of techniques offers the best of both worlds.

Acknowledgements

No acknowledgement found.

References

Cherry SR. 2006. Multimodality in vivo imaging systems: Twice the power or double the trouble? In. Annual Review of Biomedical Engineering p 35-62.

Jadvar H, Colletti PM. 2014.Competitive advantage of PET/MRI. European Journal of Radiology 83:84-94

Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Rocken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ. 2008. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nature medicine 14:459-465

Pichler BJ, Judenhofer MS, Wehrl HF. 2008. PET/MRI hybrid imaging: devices and initial results. European Radiology 18:1077-1086

Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. 2008. Positron emission tomography/magnetic resonance imaging: The next generation of multimodality imaging? Seminars in Nuclear Medicine 38:199-208

Vandenberghe S, Marsden PK. 2015. PET-MRI: a review of challenges and solutions in the development of integrated multimodality imaging. Physics in Medicine and Biology 60:R115-R154

Proc. Intl. Soc. Mag. Reson. Med. 27 (2019)